A Conversation with Anne Wojcicki
summary
Company launches consumer genetics service that drops from $1,000 for 500k SNPs to a $99 genotyping product and now offers exome sequencing at $1,000, increasing data from hundreds of thousands to tens of millions of sites. Database grows to 125,000 users, builds disease cohorts like 6,000 in Parkinson’s, and identifies a surprising protective modifier gene SGK1 in LRRK2 carriers; participant-driven analysis leads to Scripps and Michael J. Fox Foundation collaborations to test biology and druggability. Education and patient communities (e.g., 600 sarcoma members) support rapid recruitment and use.
AI-written summary · about
chapters (9)
- 0:00Introduction to 23andMe
- 1:24Genetics costs and data growth
- 2:50Consumer-driven health research
- 5:16Educating consumers and doctors
- 7:03Genetics and personal agency
- 8:05Parkinson’s disease research
- 13:19Alzheimer’s risk and prevention
- 14:22Empowering data ownership
- 15:04Prevention and lifestyle changes
related talks
20mWith Big Data Comes Big Responsibility
18mTranslating a Trillion Points of Data into New Insights into Disease
04mDBTB INT Atul Butte r
20mAdvancing Epigenetic Predictors with Scalable Machine Learning
57mBig Data and New Models Needed to Study DNA Variation in Evolution and Cancer
27mDenny Ausiello interviewed by Colin Hill
09mFighting Pediatric Cancer with Big Data
05mHadoop and Healthcare